|Mr. Douglas J. Swirsky CPA, CFA||Chief Exec. Officer, Pres, Corp. Sec. and Director||644.12k||N/A||48|
|Dr. Douglas E. Brough Ph.D.||Chief Scientific Officer||410.47k||N/A||62|
|Dr. Bryan T. Butman Ph.D.||Sr. VP of Devel.||377.12k||N/A||64|
|Mr. James Vincent Lambert||Sr. Director of Accounting & Fin., Treasurer and Corp. Controller||N/A||N/A||53|
GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform in the United States. It designs, tests, and manufactures adenoviral-based product candidates. The companys lead product candidate is CGF166, which is in Phase I/II clinical trial for the treatment of hearing loss and balance disorders. It is also developing GV2311 vaccine for respiratory syncytial virus; and GV2207 vaccine for the treatment of herpes simplex virus. The company has a collaboration agreement with Novartis AG to develop CGF166. It also has collaboration agreement with TheraBiologics, Inc. to develop cancer therapeutics; National Institute of Allergy and Infectious Diseases to generate vaccine candidates for the prevention of malaria; Laboratory of Malaria Immunology and Vaccinology to create and test various malaria vaccine candidates; and Merial to develop and commercialize vaccine and anti-viral candidates for the prevention and containment of foot-and-mouth diseases in livestock and other animals. The company was founded in 1992 and is based in Gaithersburg, Maryland.
GenVec, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.